Objective: To determine if intravenous thiamine would reduce lactate in patients with septic shock. Design: Randomized, double-blind, placebo-controlled trial. Setting: Two US hospitals. Patients: Adult patients with septic shock and elevated (> 3 mmol/L) lactate between 2010 and 2014.
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Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study
Thiamine is a key co-factor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase (1, 2) . Pyruvate dehydrogenase is the gatekeeper for entry into the Krebs Cycle without which pyruvate will be converted to lactate as opposed to acetyl-coenzyme A. Alpha-ketoglutarate dehydrogenase is required for completion of the Krebs Cycle once it has begun. Transketolase is a key enzyme for the pentose phosphate pathway and the production of NADPH. Thiamine is necessary at each of these three steps. Untreated severe thiamine deficiency (i.e., beriberi) can therefore result in inadequate functioning of aerobic metabolism resulting in elevated lactate, hypotension, and death (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
Early studies of Wernicke's Encephalopathy found infection was the most common concomitant finding, suggesting that metabolic stress may deplete remaining thiamine stores leading to disease (2) . Several studies have found thiamine deficiency to be prevalent in septic shock and other critically ill conditions, with rates ranging from 10% to 70% depending on the study design and patient population (17) (18) (19) (20) (21) . Elevated lactate, acidosis and hypotension occur in both septic shock and thiamine deficiency. Therefore, a relative or absolute thiamine deficiency state could exist in patients suffering from septic shock. We hypothesized that the provision of thiamine in patients with septic shock would lead to a reduction in lactate. We secondarily hypothesized that this effect would be greater in those with absolute thiamine deficiency.
MATERIALS AND METHODS

Design and Setting
This was a two-center, randomized, double-blind, trial comparing thiamine to placebo in patients with septic shock. The study was conducted at Beth Israel Deaconess Medical Center (coordinating site) and Baystate Medical Center, both tertiary care centers in Massachusetts, USA. The study was approved by both Institutional Review Boards, and patients or a legally authorized surrogate provided written informed consent. The trial was registered at clinicaltrials.gov (NCT01070810). The Data and Safety Monitoring Board evaluated and monitored for safety; efficacy and futility stopping points were not considered given the pilot nature of the study.
Study Population
The hospitals' emergency departments and intensive care units (ICU) were screened between January 2010 and October 2014. Inclusion criteria were: age ≥ 18 years, sepsis (presence of two or more systemic inflammatory response syndrome (SIRS) criteria with documented or suspected infection), lactate > 3 mmol/L (at the time of informed consent and randomization), and hypotension (systolic pressure < 90 mmHg) after ≥ 2 L fluid bolus followed by vasopressor-dependence. Vasopressor-dependence was defined as the continuous infusion of norepinephrine, dopamine (≥ 5 mcg/kg/min), phenylephrine, vasopressin (> 0.04 units/min) or epinephrine. Dobutamine or other inotropes at any dose were not considered vasopressors.
Exclusion criteria included: 1) liver injury or dysfunction (aspartate transaminase or alanine transaminase > 240 units/L or known cirrhosis) based on previous findings that patients with liver dysfunction may have elevated thiamine levels (17) , 2) current thiamine supplementation, 3) clinical indication for thiamine as judged by the clinical team (e.g., alcohol abuse), 4) "comfort measures only" (CMO) designation, 5) inability to provide consent, and 6) competing cause(s) of elevated lactate levels (including seizure within 3 hours, medications associated with elevated lactate (i.e. metformin, linezolid and anti-retrovirals), carbon monoxide or cyanide poisoning, known mitochondrial disorder, known/suspected bowel or limb ischemia, or cardiac arrest prior to enrollment) (17, 22, 23) . Enrollment could occur at any time during the hospitalization.
Randomization, Study Drug and Blinding
Patients were randomized to thiamine or placebo in a 1:1 ratio stratified by site. . Patients received 200 mg thiamine in 50 mL 5% dextrose or matching placebo (50 mL 5% dextrose) twice daily for 7 days or until hospital discharge. Placebo was identical in appearance to thiamine and patients, healthcare personnel and the research team remained blinded throughout the study period.
Blood Samples and Data Collection
Blood was collected at enrollment before (< 10 min) administration of the study drug (time 0) and at 6, 12 and 24 hours thereafter (± 1 hour). Blood was sent for a lactate measurement at the hospitals' clinical laboratories. Samples were centrifuged, aliquoted into light-protected cryotubes, and frozen at -80 °C. Thiamine levels were measured in plasma via Liquid Chromatography/Tandem Mass Spectrometry by Quest Diagnostics (Nichols Institute, Chantilly, VA, USA). Absolute thiamine deficiency (≤ 7 nmol/L) was determined using a previously established standard laboratory reference range.
Outcome Measures
The primary outcome was lactate level 24 hours after the first study medication dose. Secondary outcomes included lactate levels at 6 and 12 hours as well as lactate change at 24 hours (defined as (lactate at 0 hour -lactate at 24 hour)/lactate at 0 hour x 100%) and lactate ≥ 4 mmol/L at 24 hours (a commonly used cutoff indicating a high lactate level) (22, 23) . Additional outcomes included time to shock reversal (> 24 hours off all vasopressors), APACHE II score (24) at 24 hours, SOFA score (25) at 24 hours, ICU and hospital length of stay, and in-hospital mortality.
Among those who died, we classified the mode of death into one of the following categories: sudden cardiac arrest, hemodynamic shock, respiratory failure, neurological or co-morbid withdrawal of care, or "other" based on predefined criteria. The assessment of all clinical outcomes was performed by members of the investigative team who were blinded to the treatment group allocations. 
Power Calculation and Statistical Analyses
The sample size was calculated based on relative lactate change at 24 hours. Preliminary data suggested control patients would have a relative reduction of 50% with a standard deviation (SD) of 26%. We anticipated that the treatment group would have a relative reduction of 67% with a similar SD. With a type-I error of 0.05, and power of 0.80, we estimated the need for 80 patients. This estimate was increased by 10% to ensure an adequate sample size for analysis of patients with thiamine deficiency. Although the power calculation was for relative change, our primary endpoint focused on the absolute 24 h lactate based on input from the Food and Drug Administration (FDA) after the trial had begun. The change in the final analysis was approved through the DSMB prior to un-blinding.
Descriptive statistics were used to summarize the study population. Continuous variables are presented as means (SD) or medians (1 st quartile, 3 rd quartile) depending on the normality of the data. Categorical data are presented as counts with frequencies and compared between groups using Fisher's exact tests. Depending on the distribution of the data, t-tests or Wilcoxon rank sum tests were used to compare continuous data between the groups. All analysis was based on a modified intention to treat principle where all patients who received at least one dose of the study drug were included (26) . For the 24 hour time point, lactate levels were imputed based on a pre-defined plan in patients who died before this time point. If patients died before the 6 hour time point (five patients) a 20% increase from baseline was imputed, if patients died between the 6 and 12 hour time point (one patient) a 15% increase from the 6 hour time point was imputed and if patients died between the 12 and 24 hour time point (six patients) a 10% increase from the 12 hour time point was imputed.
As a pre-defined secondary analysis, we assessed the difference in lactate levels between groups over time. We utilized a repeated measures model including treatment group (thiamine and placebo), a within-subject factor (time: 0, 6, 12, and 24 hours) and the interaction between these two. An autoregressive covariance structure provided the best model fit based on the Akaike Information Criterion (AIC). Given the right-skewed distribution of the lactate levels they were logtransformed before entry in the mixed linear model and nonimputed values were used for this analysis.
Time to shock reversal was complicated by a high incidence of death prior to the event. To account for this we classified death as a competing risk event and used the estimated cumulative incidence function (CIF) to illustrate the comparison of CIFs between the two treatment groups using the Fine-Gray competing risk model (27) . We tested the subdistribution hazards of these two CIF functions and obtained the estimated hazard ratio with 95% confidence intervals. Kaplan Meier curves were created for survival and compared with the logrank test. Patients were censored at hospital discharge.
Pre-planned sub-analyses were performed in the thiamine deficient patients at the coordinating site. All hypothesis tests were two-sided, with a significance level of p < 0.05. No adjustments were made for multiple testing and all secondary outcomes should therefore be considered exploratory. Statistical analyses were conducted with the use of SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient Characteristics
Of 715 patients meeting inclusion criteria, 88 were enrolled and received the first study dose (see Fig. 1) ; 80 patients were enrolled at the coordinating site. The mean age was 67 years (SD: 16), 36 (41%) were female, and in-hospital mortality was 43%. Forty-three patients received thiamine and 45 received placebo with baseline characteristics well-balanced between the groups although patients in the thiamine group appeared to have more non-insulin dependent diabetes ( Table 1) .
Lactate
There was no difference in the primary outcome of lactate levels at 24 hours (median: 2.5 mmol/L [1.5, 3.4] vs. 2.6 mmol/L [1.6, 5.1], p = 0.40, Fig. 2) . In the repeated measures model there were statistically significantly lower lactate levels in the thiamine group at 24 hours (p = 0.048, Fig. 2 ). Relative lactate change from baseline to 24 hours was 42% (17, 51) in the thiamine group and 25% (-12, 47) in the placebo group (p = 0.16). Seventeen patients (38%) had a lactate ≥ 4 mmol at 24 hours in the placebo group compared to 9 (21%) in the thiamine group (p = 0.10). There was no difference in lactate between groups at 6 hours (p = 0.62) or 12 hours (p = 0.44).
Secondary Outcomes
We found no difference in the proportion of patients with shock reversal between the thiamine and placebo groups (74% vs. 71%, p = 0.81). In the competing risk analysis we found no difference in time to shock reversal between the thiamine and placebo groups (hazard ratio: 0.99 [95%CI: 0.61 -1.62], p = 0.97).
The APACHE II score at 24 hours was 26 (SD: 10) in the placebo group and 23 (SD: 8) in the thiamine group (p = 0.15). The 24 hour SOFA score was 8.9 (SD: 5.0) in the placebo group and 8.1 (SD: 3.5) in the thiamine group (p = 0.41). Time to ICU discharge and hospital length of stay in survivors were similar in those receiving placebo and thiamine (7 days [3, 18] vs. 8 days [4, 13] , p = 0.70) and (13 days [7, 24) vs. 13 days [8, 20] , p = 0.86). Inpatient mortality was also similar in both groups (42 vs 44%, p=1.00). There was no difference between the survival curves for the overall group (p = 0.85, Fig. 3 ) or in the mode of death (p = 0.51, Table 2 ).
change was 44% (29%, 49%) in the thiamine group and 20% (-20%, 47%) in the placebo group (p = 0.18). One (7%) patient in the thiamine group had a 24 hour lactate level ≥ 4 mmol/L compared to 5 (38%) patients in the placebo group (p = 0.07).
In the repeated measures model there were statistically significantly lower lactate levels in the thiamine group at 24 hours (p = 0.006, Fig. 2 ). There was no statistically significant difference in lactate levels at 6 (p = 0.12) or 12 hours (p = 0.10). Individual lactate levels are displayed in eFigure 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/B629; legend: Individual lactate levels over time in the thiamine deficient group. Individual lactate levels for patients with baseline thiamine deficiency in the placebo (left) and the thiamine (right) groups. Dashed lines indicate imputed values at 24 hours for those who died before the 24 hour time point.). In the thiamine group, 2 (13%) patients died compared to 6 (46%) patients in the placebo group (p = 0.10). There was a statistically significant difference between the survival curves (p = 0.047, Fig. 3 ).
There was no difference in the mode of death between groups (p = 1.00, Table 2 ).
DISCUSSION
For the group overall, we did not detect a difference in lactate levels at 24 hours, although we did find a statistically significant difference in decrease in lactate from baseline to 24 hours. We did not find any difference between groups in clinical parameters including shock reversal, survival, and length of stay. In patients who were thiamine deficient, there was a statistically significantly lower lactate at 24 hours and a decrease in lactate over time in the group who received thiamine compared to placebo. In addition, there was a statistically significant difference in time to death between the groups.
While our primary hypothesis was that thiamine would be effective for the overall group, we secondarily hypothesized that it would be particularly effective for patients with thiamine deficiency. Patients with thiamine deficiency can present with a range of dysfunctions with neurologic and cardiovascular manifestations predominating. Profound lactate elevation with acidosis has been reported in not only classic cardiac beriberi but also in Wernicke's Encephalopathy and other thiamine deficiency syndromes. Predisposition to thiamine deficiency can come from a myriad of conditions that are associated with nutritional compromise (3, (28) (29) (30) (31) (32) (33) (34) (35) .. Many of these predisposing factors may also be present in patients with septic shock. In addition to a predisposition to deficiency from underlying co-morbid disease, patients with septic shock have increased metabolic demand and often decreased nutritional intake that could theoretically deplete thiamine levels further. Prior work has shown that thiamine levels are decreased with the stress of cardiac surgery (36, 37) . Finally, Wernicke's Encephalopathy is often precipitated by an underlying stressor. In one series, concurrent infection was reported in upwards of 60% of cases of the Wernicke-Korsakoff Syndrome (2) . Septic patients may be predisposed to deficiency prior to onset of the illness and may also develop deficiency after illness onset. In the present study, 35% of patients had thiamine deficiency at baseline. The percent of deficient patients was higher than in our previous publication in septic shock (17) , likely explained by the inclusion and exclusion criteria in the current study. We targeted a population with a high risk for mortality and an increased likelihood of thiamine deficiency. For example, all patients enrolled were required to be on vasopressors with a persistent lactate > 3 mmol/L after 2 liters of intravenous fluids. In addition, we excluded patients with liver injury to avoid enrolling patients with another cause for decreased capacity to metabolize lactate and because our preliminary data illustrated that patients with acute liver failure often had high thiamine levels (17) . For all these reasons, our selected population formed a high-risk group for thiamine deficiency. At the same time, we did not include the traditional "at-risk" population of alcoholics because these patients would receive thiamine for alcoholism to prevent Wernicke's Encephalopathy as part of standard care. If alcoholics were included, the possibility remains that both the incidence of deficiency and the treatment effect of thiamine would have been increased.
Among thiamine deficient patients, we found both clinical and metabolic differences between the treatment and placebo groups. Lactate levels were lower at 24 hours in the thiamine group compared to placebo, and mortality was improved over time (Fig. 3) . The sample size for this group was small, and future studies will be necessary to validate these findings. That thiamine would decrease lactate in deficiency states is consistent with the expected pathophysiology and suggests that a sub-clinical form of beriberi may exist in patients with septic shock. Septic shock can have manifestations similar to cardiac beriberi (hypotension, hyperdynamic state, elevated lactate, acid-base patterns) and thiamine levels are not typically assessed in this disease state, therefore setting up the potential for unrecognized concomitant beriberi. Concomitant beriberi in septic shock could theoretically be even more prominent in developing countries with higher rates of nutritional deficiencies.
The mortality in the current trial was higher than recently reported studies in septic shock (38-40), but this is likely reflective of differences in the inclusion/exclusion criteria. A recent, large study from the Surviving Sepsis database reveals that mortality rates among those with hypotension and elevated lactate (i.e. the inclusion criteria in this study) were similar to the current trial (41) .
The current trial has several limitations. Enrollments were predominately from one site and generalizability may be limited. The sample size for the thiamine deficient group was small (n = 28) and therefore the results for this population need to be reproduced. Our inclusion and exclusion criteria likely led to a cohort with a high rate of deficiency. Therefore, the rate of deficiency and the potential therapeutic effect of thiamine in the overall septic population remain unknown. We did not exclude those on epinephrine, which may cause elevated lactate (22) (although this drugs was used in <10% of patients). The trial design did not specify a maximum time for enrollment and the possibility remains that the treatment effect of thiamine may have some time-dependence. Finally, while we based our dosage on historical dosages in other disease states and dosages that effectively resolved lactate elevation in cases of pure thiamine deficiency, we did not perform a dose-finding trial, and therefore the possibility remains that other regimens would be more effective.
CONCLUSION
In a randomized trial of intravenous thiamine for patients in septic shock, we did not find a difference in lactate levels between groups at 24 hours. We did, however, find a statistically significant decrease in lactate from baseline to 24 
